绝经激素治疗的类型与时机和乳腺癌风险:全球流行病学证据的个体参与者荟萃分析
该个体参与者荟萃分析汇总1992年至2018年全球前瞻性研究数据,纳入108647例绝经后乳腺癌女性,评估不同绝经激素治疗(MHT)类型与时机对乳腺癌风险的影响。除阴道雌激素外,所有MHT类型均与乳腺癌风险增加相关,且风险随使用时长增加,雌激素-孕激素联合方案高于单雌激素方案,停药后超额风险可持续10年以上。
要点
- 当前使用雌激素-孕激素者乳腺癌风险在用药第1-4年即明确升高(RR 1.60),第5-14年升至2.08。
- 当前使用单雌激素者风险亦升高,第1-4年RR 1.17,第5-14年RR 1.33,但低于联合方案。
- 第5-14年每日孕激素者风险(RR 2.30)高于间断使用(RR 1.93),异质性p<0.0001。
核心结论
- 若这些关联大部分为因果,发达国家平均体重女性50岁开始5年MHT,50-69岁乳腺癌发病率增加:雌激素+每日孕激素约每50例使用者1例,雌激素+间断孕激素约每70例1例,单雌激素约每200例1例;10年MHT相应超额约翻倍。
研究设计与样本
- 个体参与者荟萃分析,纳入所有提供MHT类型和使用时机的合格前瞻性研究,主要分析信息完整的个体。
- 1992年1月1日至2018年1月1日定期检索多个正式和非正式来源识别研究。
- 当前使用者纳入至末次报告MHT使用后5年(平均1.4年)。
- 采用逻辑回归计算调整后风险比(RR),比较特定MHT使用者与从未使用者。
主要发现
- 前瞻性随访期间,108647例绝经后女性发生乳腺癌,平均年龄65岁(SD 7);55575例(51%)曾使用MHT。
- 信息完整者中,当前使用者平均MHT持续10年(SD 6),既往使用者7年(SD 6);绝经平均年龄50岁(SD 5),开始MHT平均年龄50岁(SD 6)。
- 当前使用者第1-4年:雌激素-孕激素RR 1.60(95%CI 1.52-1.69),单雌激素RR 1.17(95%CI 1.10-1.26)。
- 当前使用者第5-14年:雌激素-孕激素RR 2.08(95%CI 2.02-2.15),单雌激素RR 1.33(95%CI 1.28-1.37)。
- 第5-14年雌激素-孕激素风险每日孕激素RR 2.30(95%CI 2.21-2.40)vs 间断使用RR 1.93(95%CI 1.84-2.01),异质性p<0.0001。
关键数值与推荐
- 当前使用第5-14年,雌激素-孕激素方案对雌激素受体阳性肿瘤的RR远高于雌激素受体阴性肿瘤。
- 40-44、45-49、50-54、55-59岁开始MHT者第5-14年RR相似,60岁后开始或肥胖者风险减弱(肥胖女性单雌激素MHT风险很小)。
- 停用MHT后部分超额风险持续10年以上,幅度取决于既往使用时长,使用不足1年者超额风险很小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Published findings on breast cancer risk associated with different types of menopausal hormone therapy (MHT) are inconsistent, with limited information on long-term effects. We bring together the epidemiological evidence, published and unpublished, on these associations, and review the relevant randomised evidence. METHODS: Principal analyses used individual participant data from all eligible prospective studies that had sought information on the type and timing of MHT use; the main analyses are of individuals with complete information on this. Studies were identified by searching many formal and informal sources regularly from Jan 1, 1992, to Jan 1, 2018. Current users were included up to 5 years (mean 1·4 years) after last-reported MHT use. Logistic regression yielded adjusted risk ratios (RRs) comparing particular groups of MHT users versus never users. FINDINGS: During prospective follow-up, 108 647 postmenopausal women developed breast cancer at mean age 65 years (SD 7); 55 575 (51%) had used MHT. Among women with complete information, mean MHT duration was 10 years (SD 6) in current users and 7 years (SD 6) in past users, and mean age was 50 years (SD 5) at menopause and 50 years (SD 6) at starting MHT. Every MHT type, except vaginal oestrogens, was associated with excess breast cancer risks, which increased steadily with duration of use and were greater for oestrogen-progestagen than oestrogen-only preparations. Among current users, these excess risks were definite even during years 1-4 (oestrogen-progestagen RR 1·60, 95% CI 1·52-1·69; oestrogen-only RR 1·17, 1·10-1·26), and were twice as great during years 5-14 (oestrogen-progestagen RR 2·08, 2·02-2·15; oestrogen-only RR 1·33, 1·28-1·37). The oestrogen-progestagen risks during years 5-14 were greater with daily than with less frequent progestagen use (RR 2·30, 2·21-2·40 vs 1·93, 1·84-2·01; heterogeneity p<0·0001). For a given preparation, the RRs during years 5-14 of current use were much greater for oestrogen-receptor-positive tumours than for oestrogen-receptor-negative tumours, were similar for women starting MHT at ages 40-44, 45-49, 50-54, and 55-59 years, and were attenuated by starting after age 60 years or by adiposity (with little risk from oestrogen-only MHT in women who were obese). After ceasing MHT, some excess risk persisted for more than 10 years; its magnitude depended on the duration of previous use, with little excess following less than 1 year of MHT use. INTERPRETATION: If these associations are largely causal, then for women of average weight in developed countries, 5 years of MHT, starting at age 50 years, would increase breast cancer incidence at ages 50-69 years by about one in every 50 users of oestrogen plus daily progestagen preparations; one in every 70 users of oestrogen plus intermittent progestagen preparations; and one in every 200 users of oestrogen-only preparations. The corresponding excesses from 10 years of MHT would be about twice as great. FUNDING: Cancer Research UK and the Medical Research Council.
引用
- Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019. PMID: 31474332. doi:10.1016/S0140-6736(19)31709-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。